A pharmacodynamic study of docetaxel in combination with the P-glycoprotein antagonist tariquidar (XR9576) in patients with lung, ovarian, and cervical cancer.

Kelly, Ronan J

A pharmacodynamic study of docetaxel in combination with the P-glycoprotein antagonist tariquidar (XR9576) in patients with lung, ovarian, and cervical cancer. [electronic resource] - Clinical cancer research : an official journal of the American Association for Cancer Research Feb 2011 - 569-80 p. digital

Publication Type: Clinical Trial; Journal Article; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural

1557-3265

10.1158/1078-0432.CCR-10-1725 doi


ATP Binding Cassette Transporter, Subfamily B, Member 1--antagonists & inhibitors
Adolescent
Adult
Aged
Aged, 80 and over
Antineoplastic Combined Chemotherapy Protocols--therapeutic use
Docetaxel
Female
Humans
Lung Neoplasms--drug therapy
Middle Aged
Ovarian Neoplasms--drug therapy
Quinolines--administration & dosage
Taxoids--administration & dosage
Uterine Cervical Neoplasms--drug therapy